Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience

Failure of autologous peripheral blood CD34+ stem cells collection can adversely affect the treatment modality for patients with hematological and nonhematological malignant diseases where high dose chemotherapy followed by hematopoietic stem cell transplantation has become part of their treatment....

Full description

Saved in:

Bibliographic Details
Published in	Transfusion and apheresis science Vol. 60; no. 3; p. 103077
Main Authors	Malinowska, Iwona, Romiszewski, Michal, Smalisz, Katarzyna, Stelmaszczyk - Emmel, Anna, Nasilowska - Adamska, Barbara, Krol, Malgorzata, Urbanowska, Elzbieta, Brozyna, Agnieszka, Baginska - Dembowska, Bozenna
Format	Journal Article
Language	English
Published	England Elsevier Ltd 01.06.2021
Subjects	Adolescent Adult Aged Aged, 80 and over Autologous peripheral blood CD34+ stem cells Autologous stem cell transplantation Benzylamines - pharmacology Benzylamines - therapeutic use Child Child, Preschool Cyclams - pharmacology Cyclams - therapeutic use Female Granulocyte Colony-Stimulating Factor - pharmacology Granulocyte Colony-Stimulating Factor - therapeutic use Hematology, Oncology, and Palliative Medicine Hematopoietic Stem Cell Mobilization - methods Humans Infant Male Middle Aged Mobilization in children Plerixafor Transplantation, Autologous - methods Young Adult Mobilization in children Autologous peripheral blood CD34+ stem cells Plerixafor Autologous stem cell transplantation Autologous peripheral blood CD34 + stem cells Autologous peripheral blood CD34(+) stem cells
Online Access	Get full text
ISSN	1473-0502 1878-1683
DOI	10.1016/j.transci.2021.103077

Cover

Abstract	Failure of autologous peripheral blood CD34+ stem cells collection can adversely affect the treatment modality for patients with hematological and nonhematological malignant diseases where high dose chemotherapy followed by hematopoietic stem cell transplantation has become part of their treatment. Plerixafor in conjunction with G-CSF is approved for clinical use as a mobilization agent. The clinical efficacy of Plerixafor in CD34+ cells collection was analyzed in our institution. A total of 13 patients aged 1–15,5 years received Plerixafor in combination with G-CSF: 7 with neuroblastoma, 2 with Ewing’s sarcoma and single patients with Hodgkin’s lymphoma, germ cell tumor, retinoblastoma and Wilms tumor. Twelve patients (923%) achieved CD34+ cell counts of ≥ 20 × 106/L after 1–7 doses of Plerixafor. The average 9,9 - fold increase in number of CD34+ cells were achieved following the first dose and 429 - fold after second dose of plerixafor. Among the 13 patients, 12 yielded the minimum required cell collection of 2 × 106/kg within an average of 2 doses of Plerixafor. The mean number of apheresis days was 1.75. The median total number of collected CD34+ cells was 982 × 106/kg. Plerixafor enables rapid and effective mobilization, and collection of sufficient number of CD34+ cells.
AbstractList	Failure of autologous peripheral blood CD34 stem cells collection can adversely affect the treatment modality for patients with hematological and nonhematological malignant diseases where high dose chemotherapy followed by hematopoietic stem cell transplantation has become part of their treatment. Plerixafor in conjunction with G-CSF is approved for clinical use as a mobilization agent. The clinical efficacy of Plerixafor in CD34 cells collection was analyzed in our institution. A total of 13 patients aged 1-15,5 years received Plerixafor in combination with G-CSF: 7 with neuroblastoma, 2 with Ewing's sarcoma and single patients with Hodgkin's lymphoma, germ cell tumor, retinoblastoma and Wilms tumor. Twelve patients (923%) achieved CD34+ cell counts of ≥ 20 × 10 /L after 1-7 doses of Plerixafor. The average 9,9 - fold increase in number of CD34 cells were achieved following the first dose and 429 - fold after second dose of plerixafor. Among the 13 patients, 12 yielded the minimum required cell collection of 2 × 10 /kg within an average of 2 doses of Plerixafor. The mean number of apheresis days was 1.75. The median total number of collected CD34 cells was 982 × 10 /kg. Plerixafor enables rapid and effective mobilization, and collection of sufficient number of CD34 cells. Failure of autologous peripheral blood CD34+ stem cells collection can adversely affect the treatment modality for patients with hematological and nonhematological malignant diseases where high dose chemotherapy followed by hematopoietic stem cell transplantation has become part of their treatment. Plerixafor in conjunction with G-CSF is approved for clinical use as a mobilization agent. The clinical efficacy of Plerixafor in CD34+ cells collection was analyzed in our institution. A total of 13 patients aged 1–15,5 years received Plerixafor in combination with G-CSF: 7 with neuroblastoma, 2 with Ewing’s sarcoma and single patients with Hodgkin’s lymphoma, germ cell tumor, retinoblastoma and Wilms tumor. Twelve patients (923%) achieved CD34+ cell counts of ≥ 20 × 106/L after 1–7 doses of Plerixafor. The average 9,9 - fold increase in number of CD34+ cells were achieved following the first dose and 429 - fold after second dose of plerixafor. Among the 13 patients, 12 yielded the minimum required cell collection of 2 × 106/kg within an average of 2 doses of Plerixafor. The mean number of apheresis days was 1.75. The median total number of collected CD34+ cells was 982 × 106/kg. Plerixafor enables rapid and effective mobilization, and collection of sufficient number of CD34+ cells. AbstractFailure of autologous peripheral blood CD34 + stem cells collection can adversely affect the treatment modality for patients with hematological and nonhematological malignant diseases where high dose chemotherapy followed by hematopoietic stem cell transplantation has become part of their treatment. Plerixafor in conjunction with G-CSF is approved for clinical use as a mobilization agent. The clinical efficacy of Plerixafor in CD34 + cells collection was analyzed in our institution. A total of 13 patients aged 1–15,5 years received Plerixafor in combination with G-CSF: 7 with neuroblastoma, 2 with Ewing’s sarcoma and single patients with Hodgkin’s lymphoma, germ cell tumor, retinoblastoma and Wilms tumor. Twelve patients (923%) achieved CD34+ cell counts of ≥ 20 × 10 6/L after 1–7 doses of Plerixafor. The average 9,9 - fold increase in number of CD34 + cells were achieved following the first dose and 429 - fold after second dose of plerixafor. Among the 13 patients, 12 yielded the minimum required cell collection of 2 × 10 6/kg within an average of 2 doses of Plerixafor. The mean number of apheresis days was 1.75. The median total number of collected CD34 + cells was 982 × 10 6/kg. Plerixafor enables rapid and effective mobilization, and collection of sufficient number of CD34 + cells. Failure of autologous peripheral blood CD34+ stem cells collection can adversely affect the treatment modality for patients with hematological and nonhematological malignant diseases where high dose chemotherapy followed by hematopoietic stem cell transplantation has become part of their treatment. Plerixafor in conjunction with G-CSF is approved for clinical use as a mobilization agent. The clinical efficacy of Plerixafor in CD34+ cells collection was analyzed in our institution. A total of 13 patients aged 1-15,5 years received Plerixafor in combination with G-CSF: 7 with neuroblastoma, 2 with Ewing's sarcoma and single patients with Hodgkin's lymphoma, germ cell tumor, retinoblastoma and Wilms tumor. Twelve patients (923%) achieved CD34+ cell counts of ≥ 20 × 106/L after 1-7 doses of Plerixafor. The average 9,9 - fold increase in number of CD34+ cells were achieved following the first dose and 429 - fold after second dose of plerixafor. Among the 13 patients, 12 yielded the minimum required cell collection of 2 × 106/kg within an average of 2 doses of Plerixafor. The mean number of apheresis days was 1.75. The median total number of collected CD34+ cells was 982 × 106/kg. Plerixafor enables rapid and effective mobilization, and collection of sufficient number of CD34+ cells.Failure of autologous peripheral blood CD34+ stem cells collection can adversely affect the treatment modality for patients with hematological and nonhematological malignant diseases where high dose chemotherapy followed by hematopoietic stem cell transplantation has become part of their treatment. Plerixafor in conjunction with G-CSF is approved for clinical use as a mobilization agent. The clinical efficacy of Plerixafor in CD34+ cells collection was analyzed in our institution. A total of 13 patients aged 1-15,5 years received Plerixafor in combination with G-CSF: 7 with neuroblastoma, 2 with Ewing's sarcoma and single patients with Hodgkin's lymphoma, germ cell tumor, retinoblastoma and Wilms tumor. Twelve patients (923%) achieved CD34+ cell counts of ≥ 20 × 106/L after 1-7 doses of Plerixafor. The average 9,9 - fold increase in number of CD34+ cells were achieved following the first dose and 429 - fold after second dose of plerixafor. Among the 13 patients, 12 yielded the minimum required cell collection of 2 × 106/kg within an average of 2 doses of Plerixafor. The mean number of apheresis days was 1.75. The median total number of collected CD34+ cells was 982 × 106/kg. Plerixafor enables rapid and effective mobilization, and collection of sufficient number of CD34+ cells.
ArticleNumber	103077
Author	Baginska - Dembowska, Bozenna Smalisz, Katarzyna Romiszewski, Michal Nasilowska - Adamska, Barbara Malinowska, Iwona Urbanowska, Elzbieta Brozyna, Agnieszka Stelmaszczyk - Emmel, Anna Krol, Malgorzata
Author_xml	– sequence: 1 givenname: Iwona orcidid: 0000-0003-0671-7849 surname: Malinowska fullname: Malinowska, Iwona email: iwona.malinowska@wum.edu.pl organization: Department of Pediatrics, Hematology and Oncology, Medical University of Warsaw, Zwirki i Wigury str. 63A, 02- 091 Warsaw, Poland – sequence: 2 givenname: Michal surname: Romiszewski fullname: Romiszewski, Michal email: michal.romiszewski@uckwum.pl organization: Department of Pediatrics, Hematology and Oncology, Medical University of Warsaw, Zwirki i Wigury str. 63A, 02- 091 Warsaw, Poland – sequence: 3 givenname: Katarzyna surname: Smalisz fullname: Smalisz, Katarzyna email: ksmalisz@wum.edu.pl organization: Department of Pediatrics, Hematology and Oncology, Medical University of Warsaw, Zwirki i Wigury str. 63A, 02- 091 Warsaw, Poland – sequence: 4 givenname: Anna surname: Stelmaszczyk - Emmel fullname: Stelmaszczyk - Emmel, Anna email: anna.stelmaszczyk-emmel@wum.edu.pl organization: Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Zwirki i Wigury str. 63A, 02- 091 Warsaw, Poland – sequence: 5 givenname: Barbara surname: Nasilowska - Adamska fullname: Nasilowska - Adamska, Barbara email: bnasilowska@ihit.waw.pl organization: Institute of Hematology and Transfusion Medicine, Warsaw, Poland Indiry Gandhi str. 14, 02-776 Warsaw, Poland – sequence: 6 givenname: Malgorzata surname: Krol fullname: Krol, Malgorzata email: bkk.csk@uckwum.pl organization: Stem Cell Bank, Central Clinical Hospital Warsaw Medical University, Poland, Zwirki i Wigury str. 63A, 02- 091 Warsaw, Poland – sequence: 7 givenname: Elzbieta surname: Urbanowska fullname: Urbanowska, Elzbieta email: bkk.csk@uckwum.pl organization: Stem Cell Bank, Central Clinical Hospital Warsaw Medical University, Poland, Zwirki i Wigury str. 63A, 02- 091 Warsaw, Poland – sequence: 8 givenname: Agnieszka surname: Brozyna fullname: Brozyna, Agnieszka email: A.Brozyna@IPCZD.PL organization: Department of Pediatrics Oncology, Children’s Memorial Health Institute, Warsaw, Poland, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland – sequence: 9 givenname: Bozenna surname: Baginska - Dembowska fullname: Baginska - Dembowska, Bozenna email: B.Dembowska@IPCZD.PL organization: Department of Pediatrics Oncology, Children’s Memorial Health Institute, Warsaw, Poland, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33583716$$D View this record in MEDLINE/PubMed
BookMark	eNqNUttu1TAQjFARvcAngPzISw6-JHEiBBU6ogWpEkiFZ8txNu0eHPvUTqDtF_SzcZrTl0qoPNlazczu7Oxhtue8gyx7zeiKUVa926zGoF00uOKUs1QTVMpn2QGrZZ2zqhZ76V9IkdOS8v3sMMYNpUyypnqR7QtR1kKy6iC7-24h4LXufSDGDy066MgfHC_Jab4-PyFzPY4wEAPWksG3aPFWj-gdQUfMJdougCNXk7bYY-LOBD2N3voLP0VyP-TWajfek3IS0V1YSHJuhEDgepvagzPwMnveaxvh1e49yn6efP6x_pKffTv9uv50lptCFmPOK94KZkynC8mZ7GvRFbIqpeGlLjnVha7rCirBi7ZnWnZctx3nGgDKumuaXhxlbxfdbfBXE8RRDRhnc9pBGljxom7KpmiKKkHf7KBTO0CntgEHHW7Uw_YS4P0CMMHHGKBXBhefyTZaxaias1IbtctKzVmpJavELh-xHxo8xTteeJDW9BshqISYV9hhADOqzuOTCh8fKRiLDo22v-AG4sZPwaUMFFORK6rO5zuaz4gzSimXs_EP_xb4jwH-Ai733RU
CitedBy_id	crossref_primary_10_3390_cancers16101821 crossref_primary_10_1089_scd_2024_0178 crossref_primary_10_3390_cells11111843 crossref_primary_10_1016_j_ejcped_2024_100161 crossref_primary_10_1002_jca_21994
Cites_doi	10.1038/s41409-019-0756-1 10.1517/14712598.8.11.1797 10.1111/trf.12265 10.1016/S0014-5793(02)03143-5 10.1016/j.transci.2013.12.017 10.1016/S1470-2045(17)30070-0 10.1038/bmt.2015.6 10.1186/1756-8722-5-14 10.1016/S1470-2045(06)70867-1 10.1111/trf.13599 10.1038/bmt.2011.216 10.1097/MPH.0b013e31821c2cb8 10.1016/j.bcp.2006.05.010 10.1002/ajh.25672 10.1200/JCO.2007.15.7628 10.1016/j.jcyt.2012.10.004 10.1002/pbc.20769 10.1038/bmt.2015.71 10.2147/DDDT.S19157 10.1634/theoncologist.2019-0898 10.1186/s13045-017-0477-0 10.1016/j.bbmt.2014.05.003 10.1038/bmt.2014.330 10.1038/sj.bmt.1705304
ContentType	Journal Article
Copyright	2021 Elsevier Ltd Elsevier Ltd Copyright © 2021 Elsevier Ltd. All rights reserved.
Copyright_xml	– notice: 2021 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2021 Elsevier Ltd. All rights reserved.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.transci.2021.103077
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1878-1683
EndPage	103077
ExternalDocumentID	33583716 10_1016_j_transci_2021_103077 S1473050221000276 1_s2_0_S1473050221000276
Genre	Journal Article
GroupedDBID	--- --K --M -RU .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 4.4 457 4G. 53G 5VS 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SDF SDG SEL SES SEW SPCBC SSH SSZ T5K UHS UNMZH Z5R ~G- AACTN AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR AAYXX ACLOT CITATION ~HD CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c474t-262b31ccda47217f83d47657c25a520a4a886e6324bf1a7d2abd22aeee58d99f3
IEDL.DBID	.~1
ISSN	1473-0502
IngestDate	Sat Sep 27 20:15:15 EDT 2025 Thu Apr 03 06:49:06 EDT 2025 Wed Oct 01 03:06:54 EDT 2025 Thu Apr 24 22:51:09 EDT 2025 Fri Feb 23 02:46:09 EST 2024 Tue Feb 25 19:55:02 EST 2025 Tue Aug 26 16:58:03 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	3
Keywords	Mobilization in children Autologous peripheral blood CD34+ stem cells Plerixafor Autologous stem cell transplantation Autologous peripheral blood CD34 + stem cells Autologous peripheral blood CD34(+) stem cells
Language	English
License	Copyright © 2021 Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c474t-262b31ccda47217f83d47657c25a520a4a886e6324bf1a7d2abd22aeee58d99f3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0003-0671-7849
PMID	33583716
PQID	2489594946
PQPubID	23479
PageCount	1
ParticipantIDs	proquest_miscellaneous_2489594946 pubmed_primary_33583716 crossref_citationtrail_10_1016_j_transci_2021_103077 crossref_primary_10_1016_j_transci_2021_103077 elsevier_sciencedirect_doi_10_1016_j_transci_2021_103077 elsevier_clinicalkeyesjournals_1_s2_0_S1473050221000276 elsevier_clinicalkey_doi_10_1016_j_transci_2021_103077
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2021-06-01
PublicationDateYYYYMMDD	2021-06-01
PublicationDate_xml	– month: 06 year: 2021 text: 2021-06-01 day: 01
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Transfusion and apheresis science
PublicationTitleAlternate	Transfus Apher Sci
PublicationYear	2021
Publisher	Elsevier Ltd
Publisher_xml	– name: Elsevier Ltd
References	Fricker, Anastassov, Cox, Darkes (bib0035) 2006; 72 Tolomelli, Mancuso, Tacchetti (bib0125) 2020; 55 Groupp, Cohn, Wall (bib0060) 2006; 46 Karres, Ali, Paula, Hennkik (bib0050) 2020; 25 Lanza, Lemoli, Olivieri (bib0090) 2014; 54 Saraceni, Shem-Tov, Olivieri (bib0030) 2015; 50 Sureda, Bader, Cesaro (bib0020) 2015 Carreras, Dufour, Mohty, Kroger (bib0015) 2019 Hong, Kang, Kim (bib0100) 2012; 5 Hubel, Fresen, Apperley (bib0070) 2012; 47 Avramova, Yordanova, Konstantinov (bib0095) 2011; 5 Lee, Lee, Cho (bib0010) 2017; 10 Duong, Savani, Copelan (bib0065) 2014; 20 Sevilla, Guillen, Castillo (bib0075) 2013; 15 Hatse, Princen, Bridger (bib0040) 2002; 527 Uy, Rettig, Cashen (bib0045) 2008; 8 Emir, Demit, Aksu (bib0085) 2014; 50 Matthay, Quach, Huberty (bib0055) 2009; 27 Sevilla, Schiavello, Madero (bib0105) 2012; 34 Gajjar, Chintagumpala, Ashley (bib0025) 2006 Ladenstein, Potschger, Pearson (bib0005) 2017; 18 Maschan, Balashov, Kurnikova (bib0115) 2015; 50 Shah, Kim, Singh (bib0120) 2020; 95 Watanabe, Watanabe, Suzuya (bib0080) 2006; 37 Teusink, Pinkard, Davies (bib0110) 2016; 56 Fricker (10.1016/j.transci.2021.103077_bib0035) 2006; 72 Uy (10.1016/j.transci.2021.103077_bib0045) 2008; 8 Sevilla (10.1016/j.transci.2021.103077_bib0075) 2013; 15 Hong (10.1016/j.transci.2021.103077_bib0100) 2012; 5 Saraceni (10.1016/j.transci.2021.103077_bib0030) 2015; 50 Lanza (10.1016/j.transci.2021.103077_bib0090) 2014; 54 Sevilla (10.1016/j.transci.2021.103077_bib0105) 2012; 34 Gajjar (10.1016/j.transci.2021.103077_bib0025) 2006 Hatse (10.1016/j.transci.2021.103077_bib0040) 2002; 527 Shah (10.1016/j.transci.2021.103077_bib0120) 2020; 95 Teusink (10.1016/j.transci.2021.103077_bib0110) 2016; 56 Ladenstein (10.1016/j.transci.2021.103077_bib0005) 2017; 18 Lee (10.1016/j.transci.2021.103077_bib0010) 2017; 10 Tolomelli (10.1016/j.transci.2021.103077_bib0125) 2020; 55 Emir (10.1016/j.transci.2021.103077_bib0085) 2014; 50 Duong (10.1016/j.transci.2021.103077_bib0065) 2014; 20 Matthay (10.1016/j.transci.2021.103077_bib0055) 2009; 27 Maschan (10.1016/j.transci.2021.103077_bib0115) 2015; 50 Sureda (10.1016/j.transci.2021.103077_bib0020) 2015 Karres (10.1016/j.transci.2021.103077_bib0050) 2020; 25 Avramova (10.1016/j.transci.2021.103077_bib0095) 2011; 5 Hubel (10.1016/j.transci.2021.103077_bib0070) 2012; 47 Carreras (10.1016/j.transci.2021.103077_bib0015) 2019 Watanabe (10.1016/j.transci.2021.103077_bib0080) 2006; 37 Groupp (10.1016/j.transci.2021.103077_bib0060) 2006; 46
References_xml	– volume: 72 start-page: 588 year: 2006 end-page: 596 ident: bib0035 article-title: Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4 publication-title: Biochem Pharmacol – volume: 5 start-page: 14 year: 2012 end-page: 16 ident: bib0100 article-title: Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment publication-title: J Hematol Oncol – volume: 20 start-page: 1262 year: 2014 end-page: 1273 ident: bib0065 article-title: Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation publication-title: Biol Blood Marrow Transp – year: 2019 ident: bib0015 article-title: The EBMT handbook – volume: 25 start-page: 1 year: 2020 end-page: 6 ident: bib0050 article-title: EMA Recommendation for the pediatric indications of Plerixafor (Mozobil) to enhance mobilization of hematopoietic stem cells for collection and subsequent autologous transplantation in children with lymphoma or malignant solid tumors publication-title: Oncologist – volume: 54 start-page: 331 year: 2014 end-page: 339 ident: bib0090 article-title: Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma publication-title: Transfusion – volume: 50 start-page: 1089 year: 2015 end-page: 1091 ident: bib0115 article-title: Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF publication-title: Bone Marrow Transp – volume: 15 start-page: 132 year: 2013 end-page: 137 ident: bib0075 article-title: Defining “poor mobilizer” in pediatric patients who need an autologous peripheral blood progenitor cell transplantation publication-title: Cytotherapy – volume: 527 start-page: 255 year: 2002 end-page: 262 ident: bib0040 article-title: Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4 publication-title: FEBS Lett – volume: 55 start-page: 946 year: 2020 end-page: 954 ident: bib0125 article-title: The timing of plerixafor addition to G-CSF and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma publication-title: Bone Marrow Transp – volume: 46 start-page: 719 year: 2006 end-page: 722 ident: bib0060 article-title: Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day publication-title: Pediatr Blood Cancer – volume: 34 start-page: 146 year: 2012 end-page: 150 ident: bib0105 article-title: Priming of hematopoietic progenitor cells by plerixafor and filgrastim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment publication-title: J Pediatr Hematol Oncol – volume: 50 start-page: 214 year: 2014 end-page: 218 ident: bib0085 article-title: Use of plerixafor for peripheral blood stem cell mobilization failure in children publication-title: Transfus Apher Sci – volume: 56 start-page: 1402 year: 2016 end-page: 1405 ident: bib0110 article-title: Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients publication-title: Transfusion – volume: 5 start-page: 407 year: 2011 end-page: 409 ident: bib0095 article-title: Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil) and granulocyte-colony stimulating factor publication-title: Drug Des Dev Ther. – volume: 18 start-page: 500 year: 2017 end-page: 514 ident: bib0005 article-title: Busulphan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial publication-title: Lancet Oncol – year: 2006 ident: bib0025 article-title: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial publication-title: Lancet Oncol – volume: 8 start-page: 1797 year: 2008 end-page: 1804 ident: bib0045 article-title: Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells publication-title: Expert Opin Biol Ther – volume: 37 start-page: 661 year: 2006 end-page: 668 ident: bib0080 article-title: Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor publication-title: Bone Marrow Transp – volume: 50 start-page: 886 year: 2015 end-page: 891 ident: bib0030 article-title: Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective publication-title: Bone Marrow Transp – volume: 47 start-page: 1046 year: 2012 end-page: 1050 ident: bib0070 article-title: European data on stem cell mobilization with plerixafor in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization publication-title: Bone Marrow Transp – start-page: 1037 year: 2015 end-page: 1056 ident: bib0020 article-title: Indications for allo- and auto-SCT for haematological diseases, solid tumors and immune diseases: current practice in Europe, 2015 publication-title: Bone Marrow Transp – volume: 10 start-page: 108 year: 2017 end-page: 119 ident: bib0010 article-title: Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study publication-title: J Hematol Oncol – volume: 27 start-page: 1020 year: 2009 end-page: 1025 ident: bib0055 article-title: Iodine-131-metaiodobenzylguanidine autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study publication-title: J Clin Oncol – volume: 95 start-page: 198 year: 2020 end-page: 204 ident: bib0120 article-title: Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts publication-title: Am J Hematol – volume: 55 start-page: 946 year: 2020 ident: 10.1016/j.transci.2021.103077_bib0125 article-title: The timing of plerixafor addition to G-CSF and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma publication-title: Bone Marrow Transp doi: 10.1038/s41409-019-0756-1 – volume: 8 start-page: 1797 year: 2008 ident: 10.1016/j.transci.2021.103077_bib0045 article-title: Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.8.11.1797 – volume: 54 start-page: 331 year: 2014 ident: 10.1016/j.transci.2021.103077_bib0090 article-title: Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma publication-title: Transfusion doi: 10.1111/trf.12265 – volume: 527 start-page: 255 year: 2002 ident: 10.1016/j.transci.2021.103077_bib0040 article-title: Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4 publication-title: FEBS Lett doi: 10.1016/S0014-5793(02)03143-5 – volume: 50 start-page: 214 year: 2014 ident: 10.1016/j.transci.2021.103077_bib0085 article-title: Use of plerixafor for peripheral blood stem cell mobilization failure in children publication-title: Transfus Apher Sci doi: 10.1016/j.transci.2013.12.017 – volume: 18 start-page: 500 year: 2017 ident: 10.1016/j.transci.2021.103077_bib0005 article-title: Busulphan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30070-0 – start-page: 1037 issue: 50 year: 2015 ident: 10.1016/j.transci.2021.103077_bib0020 article-title: Indications for allo- and auto-SCT for haematological diseases, solid tumors and immune diseases: current practice in Europe, 2015 publication-title: Bone Marrow Transp doi: 10.1038/bmt.2015.6 – volume: 5 start-page: 14 year: 2012 ident: 10.1016/j.transci.2021.103077_bib0100 article-title: Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment publication-title: J Hematol Oncol doi: 10.1186/1756-8722-5-14 – year: 2006 ident: 10.1016/j.transci.2021.103077_bib0025 article-title: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(06)70867-1 – volume: 56 start-page: 1402 year: 2016 ident: 10.1016/j.transci.2021.103077_bib0110 article-title: Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients publication-title: Transfusion doi: 10.1111/trf.13599 – volume: 47 start-page: 1046 year: 2012 ident: 10.1016/j.transci.2021.103077_bib0070 article-title: European data on stem cell mobilization with plerixafor in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization publication-title: Bone Marrow Transp doi: 10.1038/bmt.2011.216 – year: 2019 ident: 10.1016/j.transci.2021.103077_bib0015 – volume: 34 start-page: 146 year: 2012 ident: 10.1016/j.transci.2021.103077_bib0105 article-title: Priming of hematopoietic progenitor cells by plerixafor and filgrastim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment publication-title: J Pediatr Hematol Oncol doi: 10.1097/MPH.0b013e31821c2cb8 – volume: 72 start-page: 588 year: 2006 ident: 10.1016/j.transci.2021.103077_bib0035 article-title: Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2006.05.010 – volume: 95 start-page: 198 year: 2020 ident: 10.1016/j.transci.2021.103077_bib0120 article-title: Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts publication-title: Am J Hematol doi: 10.1002/ajh.25672 – volume: 27 start-page: 1020 year: 2009 ident: 10.1016/j.transci.2021.103077_bib0055 article-title: Iodine-131-metaiodobenzylguanidine autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.7628 – volume: 15 start-page: 132 year: 2013 ident: 10.1016/j.transci.2021.103077_bib0075 article-title: Defining “poor mobilizer” in pediatric patients who need an autologous peripheral blood progenitor cell transplantation publication-title: Cytotherapy doi: 10.1016/j.jcyt.2012.10.004 – volume: 46 start-page: 719 year: 2006 ident: 10.1016/j.transci.2021.103077_bib0060 article-title: Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day publication-title: Pediatr Blood Cancer doi: 10.1002/pbc.20769 – volume: 50 start-page: 1089 year: 2015 ident: 10.1016/j.transci.2021.103077_bib0115 article-title: Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF publication-title: Bone Marrow Transp doi: 10.1038/bmt.2015.71 – volume: 5 start-page: 407 year: 2011 ident: 10.1016/j.transci.2021.103077_bib0095 article-title: Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil) and granulocyte-colony stimulating factor publication-title: Drug Des Dev Ther. doi: 10.2147/DDDT.S19157 – volume: 25 start-page: 1 year: 2020 ident: 10.1016/j.transci.2021.103077_bib0050 article-title: EMA Recommendation for the pediatric indications of Plerixafor (Mozobil) to enhance mobilization of hematopoietic stem cells for collection and subsequent autologous transplantation in children with lymphoma or malignant solid tumors publication-title: Oncologist doi: 10.1634/theoncologist.2019-0898 – volume: 10 start-page: 108 year: 2017 ident: 10.1016/j.transci.2021.103077_bib0010 article-title: Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study publication-title: J Hematol Oncol doi: 10.1186/s13045-017-0477-0 – volume: 20 start-page: 1262 year: 2014 ident: 10.1016/j.transci.2021.103077_bib0065 article-title: Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation publication-title: Biol Blood Marrow Transp doi: 10.1016/j.bbmt.2014.05.003 – volume: 50 start-page: 886 year: 2015 ident: 10.1016/j.transci.2021.103077_bib0030 article-title: Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective publication-title: Bone Marrow Transp doi: 10.1038/bmt.2014.330 – volume: 37 start-page: 661 year: 2006 ident: 10.1016/j.transci.2021.103077_bib0080 article-title: Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor publication-title: Bone Marrow Transp doi: 10.1038/sj.bmt.1705304
SSID	ssj0017196
Score	2.2798204
Snippet	Failure of autologous peripheral blood CD34+ stem cells collection can adversely affect the treatment modality for patients with hematological and... AbstractFailure of autologous peripheral blood CD34 + stem cells collection can adversely affect the treatment modality for patients with hematological and... Failure of autologous peripheral blood CD34 stem cells collection can adversely affect the treatment modality for patients with hematological and...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	103077
SubjectTerms	Adolescent Adult Aged Aged, 80 and over Autologous peripheral blood CD34+ stem cells Autologous stem cell transplantation Benzylamines - pharmacology Benzylamines - therapeutic use Child Child, Preschool Cyclams - pharmacology Cyclams - therapeutic use Female Granulocyte Colony-Stimulating Factor - pharmacology Granulocyte Colony-Stimulating Factor - therapeutic use Hematology, Oncology, and Palliative Medicine Hematopoietic Stem Cell Mobilization - methods Humans Infant Male Middle Aged Mobilization in children Plerixafor Transplantation, Autologous - methods Young Adult
Title	Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1473050221000276 https://www.clinicalkey.es/playcontent/1-s2.0-S1473050221000276 https://dx.doi.org/10.1016/j.transci.2021.103077 https://www.ncbi.nlm.nih.gov/pubmed/33583716 https://www.proquest.com/docview/2489594946
Volume	60
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1878-1683 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017196 issn: 1473-0502 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1878-1683 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017196 issn: 1473-0502 databaseCode: ACRLP dateStart: 20010201 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1878-1683 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017196 issn: 1473-0502 databaseCode: .~1 dateStart: 20010201 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1878-1683 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017196 issn: 1473-0502 databaseCode: AIKHN dateStart: 20010201 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1878-1683 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017196 issn: 1473-0502 databaseCode: AKRWK dateStart: 20010201 isFulltext: true providerName: Library Specific Holdings
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEA-lgvgifntqSwRft7fJJpvksRye50dLsRb6FpJNDq6ce0fvDnzy2T_bmU12RbRUfFo2MJtNZpKZJL_fhJA34HN96UtXVM7xQkhfFs4bhYGcj4w3EOEjd_jktJ5diA-X8nKPTHouDMIq89yf5vRuts4l49yb4_ViMT5nAqxTgg9i3fkZpt3G7F9g00ffB5gHU8wkhpFCnBqieQ5-Yby26A-aBSwTOUP6eanUTf7ppviz80PTB-R-DiDpcfrHh2Qvto_I3ZN8RP6Y_DhbglF9cxCMUmgULHxjoLjbSt8Vk_MpxXJM3kxxy55-XSE4NlEx6aKlPbebdmTLOcSnnYDbddfcrnYb2jVmvXSJstQWFDcblpEiyjNe0zikTn5CLqZvv0xmRb5uoWiEEtuC19xXrGmCE7AsVHNdBaFqqRouneSlE07rOmJ6dz9nTgXufODcxRilDsbMq6dkv1218TmhwXAJ8ia4KIRyQjspgmokD7rCfD4jIvpOtk3ORY5XYixtDzq7slk3FnVjk25G5GgQW6dkHLcJ1L0Gbc80hbnRgru4TVD9TTBu8gjfWGY33Jb2DyscET1I_mbI_1Lp697ILAxyNAPXRlCt5UIbaYQR8PlnyfqGDqgqqStY9b74_4pfknv4lhBwr8j-9noXDyDW2vrDbjAdkjvHk8-fzvD5_uPs9CfBHiuh
linkProvider	Elsevier
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELZGJwEviN8UGBiJ19DEsWP7caooHVsrpG3S3iw7dqWiklZrK_En8GdzFztBCKYhXhNdHPvOd2f7-86EvIeY63KX26y0lmVcuDyzTktM5FwoWA0ZPnKHZ_Nqesk_X4mrAzLuuDAIq0y-P_r01lunJ6M0mqPNcjk6LzhYp4AYVLTnZ9UdcsgF-OQBOTw-OZ3O-8MEWehIMpIIVUNAz9EvmNcOQ0K9hJUiK5CBnkt5U4i6KQVtQ9HkIXmQckh6HH_zETkIzWNyd5ZOyZ-QH19WYFffLeSjFPoFa9_gKW640k_Z-HxC8TnWb6a4a0-_rREfG9mYdNnQjt5NW77lAlLUVsDu25tu1_stbTuzWdnIWmoyivsNq0AR6BmuaeirJz8ll5OPF-Nplm5cyGou-S5jFXNlUdfeclgZyoUqPZeVkDUTVrDccqtUFbDCu1sUVnpmnWfMhhCE8lovymdk0Kyb8IJQr5kAee1t4FxarqzgXtaCeVViSZ8h4d0gmzqVI8dbMVamw519NUk3BnVjom6G5EMvton1OG4TqDoNmo5sCu7RQMS4TVD-TTBs0yTfmsJsmcnNH4Y4JKqX_M2W_6XRd52RGZjnaAa2CaBaw7jSQnPN4fPPo_X1A1CWQpWw8H35_w2_JfemF7Mzc3YyP31F7uObCIh7TQa76304gtRr596kqfUTcXsstw
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plerixafor+combined+with+G-CSF+for+stem+cell+mobilization+in+children+qualified+for+autologous+transplantation-+single+center+experience&rft.jtitle=Transfusion+and+apheresis+science&rft.au=Malinowska%2C+Iwona&rft.au=Romiszewski%2C+Michal&rft.au=Smalisz%2C+Katarzyna&rft.au=Stelmaszczyk+-+Emmel%2C+Anna&rft.date=2021-06-01&rft.pub=Elsevier+Ltd&rft.issn=1473-0502&rft.eissn=1878-1683&rft.volume=60&rft.issue=3&rft_id=info:doi/10.1016%2Fj.transci.2021.103077&rft.externalDocID=S1473050221000276
thumbnail_m	http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14730502%2FS1473050221X00043%2Fcov150h.gif